Skip to main content
micro-community-banner
 
  • Saved

made a Post

Quercetin Attenuates Nitroglycerin-Induced Migraine Headaches by Inhibiting Oxidative Stress and Inflammatory Mediators - PubMed

This study aimed to investigate the antimigraine potential of quercetin in migraine pain induced by nitroglycerin (NTG), 10 mg/kg, intraperitoneal injection in rats. Quercetin was administered orally for 1 week, ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36432556/


Conclusions: Therefore, it was concluded that quercetin improved the pain behavior of migraine patients in the NTG-induced migraine rat model. Quercetin is thought to have antimigraine effects due to its antioxidant and anti-inflammatory potential. Quercetin may therefore be a novel agent that can treat or prevent migraine pain and associated...

  • Saved

made a Post

Effectiveness and Safety of Chronic Migraine Preventive Treatments: A Systematic Literature Review - PubMed

doi: 10.1007/s40122-022-00452-3. Online ahead of print. 1 The Los Angeles and San Diego Headache Centers, San Diego, CA, USA. 2 Bridge Medical Consulting Ltd, Richmond, London, UK. 3 AbbVie, 2525 ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36417165/


Conclusions: "Conclusion: While substantial real-world evidence supports the long-term effectiveness and safety of onabotulinumtoxinA, real-world data on other preventive treatments of CM are currently limited to short term effectiveness due to their more recent approvals."


  • Saved

made a Post

A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study - PubMed

doi: 10.1186/s10194-022-01514-9. 1 Chinese PLA General Hospital, Beijing, China. [email protected] 2 Nowon Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea. 3 Hebei General Hospital, Shijiazhuang, China. 4 The ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36404301/


Conclusions: "DRAGON study demonstrated the efficacy and safety of erenumab 70 mg in patients with CM from Asia. No new safety signals were observed during the DBTP compared with the previous trials."


  • Saved

made a Post

Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results - PubMed

doi: 10.1186/s10194-022-01515-8. 1 Department of Neurology and Neurorehabilitation, ZURZACH Care, Bad Zurzach, Switzerland. [email protected] 2 Kopfwehzentrum Hirslanden, Zurich, Switzerland. 3 Department of Neurology, Inselspital, University Hospital Bern and University of ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36401172/


Conclusions: Overall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced."

  • Saved

Commented on 's Post

Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study - The Journal of Headache and Pain

Objective HER-MES was the first head-to-head, phase 4 trial to assess the tolerability and effectiveness of erenumab against standard of care treatment (topiramate). This post hoc analysis compared the efficacy ..... see more

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01511-y


Conclusions: This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD with an early onset of efficacy."


Show More Comments

  • November 22, 2022
    Key Points • Source: The Journal of Headache and Pain • Conclusion: “This post hoc analysis demonstrated significantly superior efficacy of erenumab versus topiramate in achieving a ≥50% reduction in MMD [monthly migraine days] Show More
  • Saved

made a Post

Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study

To identify predictors of acute treatment optimization with prescription drugs among people with episodic migraine. A total of 2896 individuals from the American Migraine Prevalence and Prevention study were included ..... see more

Source : https://www.sciencedirect.com/science/article/abs/pii/S0303846722003924?via=ihub

/>

Conclusions: Almost half of study respondents were not optimized on their usual prescription acute migraine treatment(s). Predictive models identified several features associated with treatment optimization.


  • Saved

made a Post

Effect of Atogepant for Preventive Migraine Treatment on Patient-Reported Outcomes in the Randomized, Double-blind, Phase 3 ADVANCE Trial

Background and Objectives: The oral calcitonin gene-related peptide receptor antagonist atogepant is indicated for the preventive treatment of episodic migraine. We evaluated changes in patient-reported outcomes with atogepant in adults ..... see more

Source : https://n.neurology.org/content/early/2022/11/17/WNL.0000000000201568


Discussion: Atogepant 30 and 60mg produced significant improvements in key patient-reported outcomes including MSQ-RFR scores and both AIM-D domains. Nominal improvements also occurred for other MSQ domains and HIT-6, reinforcing the beneficial effects of atogepant as a new treatment for migraine prevention.


  • Saved

made a Post

Different dosage regimens of erenumab for the treatment of migraine: A systematic review and meta-analysis of the efficacy and safety of randomized controlled trials - PubMed

Background: Migraine is a worldwide epidemic neurological disorder that has a significant influence on the quality of life. Migraine attacks are considered to be related to a calcitonin gene-related peptide ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36373822/


Conclusions: In our study, we found that erenumab, especially at the dose of 140 mg, is an effective and well-tolerated preventive treatment for migraine.


"

  • Saved

made a Post

Salivary Endocannabinoid Profiles in Chronic Orofacial Pain and Headache Disorders: An Observational Study Using a Novel Tool for Diagnosis and Management - PubMed

The endocannabinoid system is involved in physiological and pathological processes, including pain generation, modulation, and sensation. Its role in certain types of chronic orofacial pain (OFP) has not been thoroughly ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36361803/


Conclusions: Salivary samples exhibited signature eCBs profiles for major OFP disorders, especially migraine, TTH, TN, and BMS. This finding may pave the way for using salivary eCBs biomarkers for more accurate diagnoses and management of chronic OFP patients.


  • Saved

made a Post

Adverse Events Reported with Therapies Targeting the CGRP Pathway During the First 6 Months Post-launch: A Retrospective Analysis Using the FDA Adverse Events Reporting System - Advances in Therapy

Introduction Through 2018, three calcitonin gene-related peptide pathway-targeted monoclonal antibodies (CGRP mAbs) had received US Food and Drug Administration (FDA) approval for migraine prevention: erenumab, fremanezumab, and galcanezumab. see more

Source : https://link.springer.com/article/10.1007/s12325-022-02346-4


Conclusions: "Conclusion: These results aid in supporting the safety profile of CGRP mAbs in the real-world setting and may provide clinicians and patients with additional insight when considering migraine preventive treatments."


  • Saved

made a Post

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients - The Journal of Headache and Pain

Background and objectives The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% ..... see more

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01498-6


Conclusions: "Conclusions: A critical evaluation of headache characteristics indicating peripheral or central sensitization may help in predicting responsiveness to antiCGRP mAbs in HFEM and CM. A more precise pain profiling may represent a steppingstone for a mechanism-based approach and personalized treatment of migraine with compounds...

  • Saved

made a Post

Two-year effectiveness of erenumab in resistant chronic migraine: a prospective real-world analysis - The Journal of Headache and Pain

Background Controlled and real-world evidence have demonstrated the efficacy of calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine. However, data on the over-one-year sustained effectiveness of CGRP MABs ..... see more

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01507-8


Conclusions: Long-term sustained effectiveness of erenumab was reported only by a minority of resistant CM patients. Although more research in resistant migraine is needed, Erenumab can provide long-term meaningful reduction in migraine load and migraine-related disability in some patients.


  • Saved

made a Post

Refractory Headaches

Semin Neurol 2022; 42(04): 512-522DOI: 10.1055/s-0042-1757925 1   Headache Specialist at Hartford HealthCare, Hartford, Connecticut 3   Department of Neurology, Brigham and Women's Faulkner Hospital J Graham Headache Center, Boston, ..... see more

Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-1757925


Relevance: Medication overuse headache (MOH), new daily persistent headache (NDPH), and persistent refractory headache attributed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection represent a significant burden in terms of disability and quality of life, and a challenge in terms of definition, pathophysiology, and...

  • Saved

made a Post

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study - Journal of Neurology

Introduction Although migraine prevalence decreases with aging, some older patients still suffer from chronic migraine (CM). This study aimed to investigate the outcome of OnabotulinumtoxinA (OBT-A) as preventative therapy in ..... see more

Source : https://link.springer.com/article/10.1007/s00415-022-11457-5


Conclusions: In a population of elderly CM patients with a long history of migraine OBT-A provided a significant benefit, over the first three treatment cycles, as good as in non-old patients.


  • Saved

made a Post

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients - The Journal of Headache and Pain

Background and objectives The identification of predictors of response to antiCGRP mAbs could favor tailored therapies and personalized treatment plans. This study is aimed at investigating predictors of ≥ 50%, ≥ 75% ..... see more

Source : https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-022-01498-6


Conclusions: "A critical evaluation of headache characteristics indicating peripheral or central sensitization may help in predicting responsiveness to antiCGRP mAbs in HFEM and CM. A more precise pain profiling may represent a steppingstone for a mechanism-based approach and personalized treatment of migraine with compounds targeting specific...

  • Saved

made a Post

The contribution of the left precuneus to emotion memory in migraine without aura patients

BackgroundThe impact of migraine without aura (MWoA) on cognitive function remains controversial, especially given the sparse literature on emotional memory.MethodsTwenty seven MWoA patients and 25 healthy controls (HCs) were enrolled ..... see more

Source : https://www.frontiersin.org/articles/10.3389/fnins.2022.905942/full


Conclusions: Our study demonstrated the tendency for the influence of migraine on emotional memory and revealed the left precuneus as a critical contributor to recollection performance, providing novel insights for understanding emotional memory and its neural mechanisms in MWoA patients.


  • Saved

Commented on 's Post

Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome?

A significant association between migraine and restless legs syndrome (RLS) has been reported, and their coexistence is not uncommon. We report a patient with concomitant migraine and RLS who showed ..... see more

Source : https://www.jns-journal.com/article/S0022-510X(22)00324-0/fulltext


Conclusions: We report a case of improvement of both migraine and RLS after treatment with CGRP monoclonal antibody. Additional studies are needed to clarify how CGRP antagonism affects RLS symptoms in patients with migraine and RLS comorbidity.

Show More Comments

  • October 31, 2022
    Key Points • Source: Journal of the Neurological Sciences • Conclusion: “We report a case of improvement of both migraine and RLS [restless legs syndrome] after treatment with CGRP monoclonal antibody. Additional studies are Show More
  • Saved

made a Post

Serum Calcitonin Gene-Related Peptide Is Elevated in... : Journal of Neuro-Ophthalmology

pathy [RPON]). As migraine is associated with elevated serum calcitonin gene-related peptide (CGRP) levels, we studied serum CGRP levels among patients with OM/RPON to determine whether they are elevated during ..... see more

Source : https://journals.lww.com/jneuro-ophthalmology/Abstract/9900/Serum_Calcitonin_Gene_Related_Peptide_Is_Elevated.194.aspx


Conclusions: Elevated serum CGRP levels during the ictal phase of OM/RPON favor migraine as the underlying cause of episodic headache with ophthalmoplegia.

  • Saved

made a Post

Calcitonin Gene-Related Peptide (CGRP) and Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) in Migraine Pathogenesis - PubMed

2022 Sep 27;15(10):1189. doi: 10.3390/ph15101189. 1 Danish Headache Center, Department of Neurology, Rigshospitalet Glostrup, Glostrup, 2600 Copenhagen, Denmark. 2 Department of Neurorehabilitation/Traumatic Brain Injury, Rigshospitalet, 2100 Copenhagen, Denmark. Free PMC ..... see more

Source : https://pubmed.ncbi.nlm.nih.gov/36297301/


Conclusions: Human studies into the pathophysiological underpinnings of CGRP and PACAP in migraine are manifold and here we review the works investigating these neuropeptides in patients suffering from migraine in order to elucidate the background for developing new treatment options for this vastly disabling disorder.


  • Saved

Blood Pressure in Migraine Patients Treated With Monoclonal Anti-CGRP (receptor) Antibodies: A Prospective Follow-up Study

Background and Objectives: Anti-CGRP (receptor) antibodies are approved as preventive treatment for migraine. Recent concerns have been raised after a retrospective analysis of post-marketing case reports of elevated BP associated ..... see more

Source : https://n.neurology.org/content/early/2022/10/04/WNL.0000000000201008


Discussion: The mean systolic and diastolic BP increased after anti-CGRP (receptor) antibodies were started. The majority of patients remained within the normal blood pressure limits, but some patients required antihypertensive treatment. Physicians should be aware that people with migraine may be at risk to develop hypertension when treated...

Show More Comments